Press Releases

2013-05-22
Affibody AB and Daewoong Pharmaceutical Co., Ltd. enter into a License Agreement regarding the Albumod™ platform
Solna, Sweden, May 22, 2013. Affibody is pleased to announce a collaboration with Daewoong Pharmaceutical Co., Ltd.

2013-05-22
Affibody AB receives SwedenBIO award 2013
Solna, Sweden, May 22, 2013. Affibody wins SwedenBIO Award 2013 for its unique business model.

2013-04-30
First Patient Included in PET Imaging Study of HER2 Expression in Metastatic Breast Cancer
Solna, Sweden, April 30, 2013. Affibody is pleased to announce that the first patient has been enrolled in a clinical study to evaluate ABY-025 for PET imaging of HER2 expression in subjects with metastatic breast cancer.

2013-02-15
Year End Report 2012
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM, today issued its Year-End Report for 2012.

2012-11-01
Interim Report – January to September 2012
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM, today issued its Interim Report covering the first nine months of 2012.

2012-08-07
Interim Report – January to June 2012
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM, today issued its Interim Report covering the First Half of 2012.

2012-07-10
Sobi enters Research Collaboration with Affibody within the IL-1 field
Solna, July 10, 2012. Sobi has signed a research collaboration and option agreement with the Swedish biotech company Affibody AB for the discovery and development of novel treatments for inflammatory diseases where Interleukin-1 (IL-1) is implicated.

2012-06-02
GE Healthcare and Affibody AB to Collaborate on Her2 specific PET Imaging Agent for Breast and Gastric Cancer
ST Giles Chalfont, UK, & Solna, Sweden, June 02, 2012. GE Healthcare signed an agreement with Affibody AB (“Affibody”) to collaborate on the development of a Her2-targeted PET imaging agent, which is scheduled to begin clinical trials later this year.

2012-04-27
Interim Report – January to March 2012
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM, today issued its Interim Report covering the First Quarter 2012.

2012-03-21
Notice of Annual General Meeting
Kallelse till årsstämma

2012-02-10
Year-End Report 2011
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM, today issued its Year-End Report for 2011.

2012-02-02
Affibody AB and Creative Antibiotics AB enter collaboration to develop targeted antibiotics.
Solna, February 2, 2012. Affibody AB today signed an agreement with Creative Antibiotics AB with the aim of developing pharmaceutical candidates targeting gram negative bacteria.

2011-12-20
Affibody AB and Nuclisome AB to Develop Cancer Therapeutics
Solna, Sweden, December 20, 2011. Affibody AB today announced a collaboration agreement with Nuclisome AB with the aim of developing new cancer therapeutics.

2011-12-09
First-in-Human Whole-Body HER2-Receptor Mapping Using Affibody Molecular Imaging with ABY-025
Solna, Sweden, December 9, 2011. Affibody is pleased to announce that clinical imaging data using anti-HER2 Affibody® molecules have been presented at the 34th San Antonio Breast Cancer Symposium in San Antonio, USA (http://www.sabcs.org/).

2011-11-22
Notice of Extraordinary General Meeting
Kallelse till extra bolagsstämma

2011-10-26
Interim Report – January to September 2011
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM, today issued its Interim Report covering the first nine months of 2011.

2011-09-19
Affibody appoints Dr. Fredrik Frejd as VP Research
Stockholm, September 19, 2011. Affibody AB announced today that Ass. Prof. Fredrik Frejd has been appointed to VP Research. Dr. Frejd has worked at Affibody AB since 2002, most recently as Director Discovery.

2011-09-09
Affibody AB and GE Healthcare Expands its Relationship in the Field of Large-scale Affinity Purification
STOCKHOLM, Sweden, September 9, 2011 - Affibody AB and GE Healthcare, a division of the General Electric Company, has today expanded its relationship in the field of large-scale affinity purification.

2011-08-09
Interim Report – January to June 2011
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM, today issued its Interim Report covering the First Half of 2011.

2011-06-13
Affibody to Present at Next Generation Protein Therapeutics Summit in San Francisco
Affibody AB will give a presentation titled “From Clinical Imaging to Serum Half-life Extension Using HER2-Specific Affibody Molecules” at Next Generation Protein Therapeutics Summit, taking place June 20-22, 2011 in San Francisco, California.

2011-05-05
Interim Report – January to March 2011
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM, today issued its Interim Report covering the First Quarter 2011.

2011-05-04
Algeta ASA obtains licenses to develop cancer therapeutics based on Affibody® technology for two oncology targets
Affibody AB today signed a license and collaboration agreement with Algeta ASA (OSE: ALGETA) with the aim of developing new tumor-targeting alpha-pharmaceutical candidates based on the alpha particle emitter thorium-227.

2011-03-03
Year-End Report 2010
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM, today issued its Year-End Report for 2010.

2011-01-05
Affibody to Present at CHI's 10th Annual PepTalk in San Diego
Affibody AB will give a presentation titled “Engineering of the Albumin Binding Domain (ABD) for Half-life Extension Applications” at CHI's 10th Annual PepTalk 2011, taking place January 10-14, 2011 in San Diego, California.